These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 5388075)

  • 1. Effect of reserpine injections in migrainous and normal control subjects, with estimations of urinary 5-hydroxyindoleacetic acid.
    Tandon RN; Sur BK; Nath K
    Neurology; 1969 Nov; 19(11):1073-9. PubMed ID: 5388075
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationships between headache and amine changes after administration of reserpine to migrainous patients.
    Curzon G; Barrie M; Wilkinson MI
    J Neurol Neurosurg Psychiatry; 1969 Dec; 32(6):555-61. PubMed ID: 5364727
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluctuation of 5-hydroxy-indole compounds in the urine of migrainous patients.
    Deanović Z; Iskrić S; Dupelj M
    Biomedicine; 1975 Nov; 23(9):346-9. PubMed ID: 1231931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of reserpine on amino-acid excretion in patients with migraine.
    Kimball RW; Goodman MA
    J Neurol Neurosurg Psychiatry; 1966 Jun; 29(3):190-1. PubMed ID: 5937631
    [No Abstract]   [Full Text] [Related]  

  • 5. Cerebrospinal fluid 5-hydroxyindoleacetic acid level in migrainous patients during spontaneous attacks, during headache-free periods and following treatment with L-tryptophan.
    Poloni M; Nappi G; Arrigo A; Savoldi F
    Experientia; 1974 Jun; 30(6):640-1. PubMed ID: 4837086
    [No Abstract]   [Full Text] [Related]  

  • 6. [The effect of reserpine on serotonin metabolism in patients with schizophrenia and reactive conditions].
    Zabrodin GD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1974; 74(8):1185-91. PubMed ID: 4417086
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of Deseril-Retard and Migristen on the excretion of 5-hydroxy-indoloacetic acid and P-hydroxy-M-methoxymandelic acid in the urine of patients suffering from migraine].
    Stein W; Kawiak W; Stelmasiak Z; Gieracz A
    Ann Univ Mariae Curie Sklodowska Med; 1969; 24():309-20. PubMed ID: 5406037
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
    Hartvig P
    J Oncol Pharm Pract; 2007 Mar; 13(1):57-8. PubMed ID: 17621570
    [No Abstract]   [Full Text] [Related]  

  • 9. [Urinary excretion of 5-hydroxyindoleacetic acid during headache attacks induced with trinitroglycerin].
    Campus S; Fabris F; Rappelli A; Gastaldi L; Gai V; Nattero G
    Boll Soc Ital Biol Sper; 1967 Dec; 43(24):1844-7. PubMed ID: 4971948
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and biochemical effects of fenclonine: a serotonin depletor.
    Cremata VY; Koe BK
    Dis Nerv Syst; 1968 May; 29(5):Suppl:147-52. PubMed ID: 5673619
    [No Abstract]   [Full Text] [Related]  

  • 11. A critical review of the treatment of migrainous neuralgia.
    Mann P; Sutherland JM; Eadie MJ
    Proc Aust Assoc Neurol; 1970; 7():49-53. PubMed ID: 5514825
    [No Abstract]   [Full Text] [Related]  

  • 12. Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine.
    Brion N; Bons J; Plas J; Bayliss EM; Advenier C
    Cephalalgia; 1989; 9 Suppl 9():79-82. PubMed ID: 2544288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies in migraine.
    Lance JW
    Proc Aust Assoc Neurol; 1966; 4():81-4. PubMed ID: 5966206
    [No Abstract]   [Full Text] [Related]  

  • 14. [Value of the piribedil test in diagnosing migraine. Apropos of 150 cases].
    Géraud G; Bès A; Courtade M; Dupui P; Guell A
    Rev Neurol (Paris); 1983; 139(3):215-8. PubMed ID: 6612136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of reserpine injection on methysergide treated control and migrainous subjects.
    Carroll JD; Hilton BP
    Headache; 1974 Oct; 14(3):149-56. PubMed ID: 4430604
    [No Abstract]   [Full Text] [Related]  

  • 16. Serotonin-releasing factors in migrainous patients.
    Mück-Seler D; Deanović Z; Dupelj M
    Adv Neurol; 1982; 33():257-64. PubMed ID: 6172961
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
    Higa GM; Auber ML; Altaha R; Piktel D; Kurian S; Hobbs G; Landreth K
    J Oncol Pharm Pract; 2006 Dec; 12(4):201-9. PubMed ID: 17156592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histaminuria in vascular headache.
    Sjaastad O; Sjaastad OV
    Acta Neurol Scand; 1970; 46(3):331-42. PubMed ID: 5505975
    [No Abstract]   [Full Text] [Related]  

  • 19. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
    Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
    Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urinary excretion of 5-hydroxyindoleacetic acid by patients with chronic schizophrenia].
    Slowik S
    Psychiatr Pol; 1967; 1(1):45-52. PubMed ID: 5597271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.